Dyne Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Director and Officer Trading Arrangements
The following table describes, for the period covered by this Quarterly Report, each trading arrangement for the sale or purchase of Company securities adopted orterminated by our directors and officers that is a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”). For the period covered by this Quarterly Report, none of our directors or officers adopted or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
| Name | Title | Action Taken | Date | Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Douglas Kerr, M.D. | Chief Medical Officer | Adopted | March 18, 2026 | 34,652* | June 17, 2027 |
*In addition to 10% of the number of shares acquired upon the vesting of restricted stock units after a sell-to-cover transaction to satisfy tax withholding obligations, which number cannot be determined at this time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.